Clinical trial of Zhixue Quyu Mingmu Tablet in the treatment of ocular fundus hemorrhage after its release

Phase 4

• Conditions: Submacular hemorrhage

• Registration Number: ITMCTR2000003529
• Lead Sponsor: Peking Union Medical College Hospital, Chinese Academy of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 20 February 2023

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

1. Patients with submacular hemorrhage in at least one eye;
2. Those who meet the syndrome differentiation criteria of yin deficiency and liver hyperactivity and heat injury of collaterals;
3. Over 18 years old;
4.Best corrected visual acuity (BCVA) measured by visual acuity chart: the letters of BCVA can be clearly seen by standard logarithmic visual acuity chart, ranging from 0.05 (including 0.1) to 0.6;
5. The refractive stroma is clear and does not interfere with fundus examination and fundus fluorescein angiography;
6. Patients should have good compliance with the observation and evaluation of the efficacy of the researchers;
7. Those who did not participate in other clinical trials within 2-4 weeks before treatment;
8. Those who sign informed consent.

Exclusion Criteria

1. Wet age-related macular degeneration was completely scarred without bleeding and exudation;
2. Fundus refractive stroma unclear (such as vitreous hemorrhage, cataract) affect the fundus condition of the observer;
3. Severe cardiovascular and cerebrovascular diseases, liver, kidney and hematopoiesis diseases;
4. Mental patients;
5. Severe allergy to sodium fluorescein injection;
6. Risk of thrombosis
7. Patients who are participating in clinical trials of other drugs; patients who use the same kind of traditional Chinese medicine and other treatments; or those who quit halfway.

Study & Design

• Study Type: Observational study
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Vision improvement within 6 months;